Aktis Oncology
Cambridge, United States · Biotechnology, Health Care, Therapeutics · 41 employees
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.
Funding history
- Funding Round — $175.0M — Oct 2024
- Series series b — $175.0M — Sep 2024
- Funding Round — $84.0M — Aug 2022
Recent signals
- Jan 12, 2026: SEC 8-K (5.03): On January 12, 2026, Aktis Oncology, Inc. filed an amended and restated certificate of incorporation in connection with its initial public offering (IPO). The Amended and Restated Certificate authorizes a total of 480,000,000 shares of Common Stock and 10,000,000 shares of preferred stock. This amendment is significant as it updates the company's capital structure to accommodate the shares being issued during the IPO. The filing indicates a strategic milestone for the company, embarking on public trading to enhance capital access for growth initiatives.
- Nov 05, 2025: Aktis Oncology Appoints Kyle Kuvalanka as Chief Financial Officer
- Oct 02, 2024: Raised $175.0M
- Sep 30, 2024: Raised $175.0M in Series series b
- Jul 09, 2024: Aktis Oncology Appoints Akos Czibere, MD, PhD, as Chief Medical Officer
- May 30, 2024: Aktis Oncology Promotes Tyler Benedum, Ph.D., to Chief Technical Officer
- Aug 25, 2022: Raised $84.0M
See plans & pricing → Track Aktis Oncology’s funding, hiring, and signals — with verified contacts — on Fundz.